C-Further Unveils First Therapeutic Programmes Dedicated to Paediatric Oncology
MiNK Therapeutics, Inc. (INKT)
Company Research
Source: Business Wire
C-Further to advance its first two bespoke paediatric cancer therapeutics in collaboration with leading global academic and industry investigatorsSelected programmes to potentially address multiple children’s cancers including Ewing sarcoma, bone sarcoma, medulloblastoma and acute myeloid leukaemiaAdditional C-Further programmes to be announced in 2026 LONDON--(BUSINESS WIRE)--C-Further, an international consortium committed to creating new therapeutics for childhood cancers, today unveils the first early-stage therapeutic programmes for its pipeline, dedicated to paediatric oncology indications. Through its collaborative model, C-Further has partnered with investigators at UVA Comprehensive Cancer Center, Dana-Farber Cancer Institute and Mass General Brigham to advance CF-012 for the potential treatment of Ewing sarcoma. In parallel, the consortium has partnered with investigators at MiNK Therapeutics (Nasdaq: INKT) to advance CF-033, leveraging MiNK’s proprietary platform with tr
Show less
Read more
Impact Snapshot
Event Time:
INKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INKT alerts
High impacting MiNK Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
INKT
News
- MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers [Yahoo! Finance]Yahoo! Finance
- MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric CancersGlobeNewswire
- C-Further Unveils First Therapeutic Programmes Dedicated to Paediatric Oncology [Yahoo! Finance]Yahoo! Finance
- MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia [Yahoo! Finance]Yahoo! Finance
- MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone SymposiaGlobeNewswire
INKT
Earnings
- 11/14/25 - Beat
INKT
Sec Filings
- 3/11/26 - Form 4
- 3/4/26 - Form 4
- 1/14/26 - Form 4/A
- INKT's page on the SEC website